New Insights into Mesenchymal Stromal Cell-Mediated T-Cell Suppression Through Galectins

Scandinavian Journal of Immunology

Volumn 73, Issue 2, 2011, Pages 79-84

  Sioud, M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 1; GALECTIN 3; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; PROSTAGLANDIN E2; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA;

CELL CONTACT; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION; GENE REPRESSION; HUMAN; IMMUNOMODULATION; MESENCHYMAL STROMAL CELL; MESENCHYME CELL; MIXED LYMPHOCYTE REACTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; GALECTINS; GENE EXPRESSION REGULATION; HUMANS; MESENCHYMAL STEM CELLS; STROMAL CELLS; T-LYMPHOCYTES;

EID: 78650761735     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02491.x     Document Type: Review

References (57)

1. Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006;18:586-91.
2. Bianco P, Gehron Robey P. Marrow stromal stem cells. J Clin Invest 2000;105:1663-8.
3. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7.
4. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 2002;99:3838-43.
5. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-506.
6. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006;24:74-85.
7. Spaggiari GM, Abbelrazik H, Becchetti F, Moretta L. MSCs inhibit monocytes-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009;113:6583-96.
8. Asari S, Itakura S, Ferreri K et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009;37:604-15.
9. Tabera S, Pérez-Simón JA, Díez-Campelo M et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008;93:1301-9.
10. Di Ianni M, Del Papa B, De Ioanni M et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008;36:309-18.
11. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007;92:881-8.
12. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:579-86.
13. Duijvestein M, Vos AC, Roelofs H et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study Gut 2010 (in press).
14. Müller I, Kordowich S, Holzwarth C et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008;40: 25-32.
15. Ringdén O, Uzunel M, Sundberg B et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007;21:2271-6.
16. Tyndall A, LeBlanc K. Stem cells and rheumatology: update on adult stem cell therapy in autoimmune diseases. Artritis Rheum 2006;55:521-5.
17. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003;76:1208-13.
18. Sundin M, Barrett AJ, Ringdén O et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 2009;32:755-64.
19. Sundin M, Ringdén O, Sundberg B, Nava S, Götherström C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007;92:1208-15.
20. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
21. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-21.
22. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-50.
23. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007;149:353-63.
24. Sioud M, Fløisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol 2007;37:2834-46.
25. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008;26:99-107.
26. Liotta F, Angeli R, Cosmi L et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can be inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008;26:279-89.
27. Sioud M, Fløisand Y. NOD2/CARD15 on bone marrow CD34+ hematopoietic cells mediates induction of cytokines and cell differentiation. J Leukoc Biol 2009;85:939-46.
28. Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scan J Immunol 2010;71:267-74.
29. van Kooyk Y, Rabinovich GA. Protein glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008;9:593-601.
30. Hirabayashi J, Hashidate T, Arata Y et al. Oligosaccharide specificity of galectins: a search by fromtal affinity chromatography. Biochim Biophys Acta 2002;1572:232-54.
31. Laderach DJ, Compagno D, Toscano MA et al. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings. IUBMB Life 2010;62:1-13.
32. Stowell SR, Cho M, Feasley CL et al. Ligand reduces galectin-1 sensitivity to oxidative inactivation by enhancing dimmer formation. J Biol Chem 2009;284:4989-99.
33. Toscano MA, Bianco GA, Ilarregui JM et al. Differential glycosylation of Th-1, TH-2 and Th17 effector cells selectively regulates susceptibility to cell death. Nature Immunol 2007;8:825-34.
34. Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol (in press).
35. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006;16:137R-57R.
36. Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T cell functions. Immunol Rev 2009;230:114-27.
37. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736-9.
38. Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. CD7 delivers a proapoptotic signal during galectin-1-induced T cell death. J Immunol 2000;165:2331-4.
39. Fukumori T, Takenaka Y, Yoshii T et al. CD29 and CD7 mediate galectin-3-induced type T-cell apoptosis. Cancer Res 2003;63:8302-11.
40. Zhu C, Anderson AC, Schubart A et al. The Tim-3 ligand galectin-9 negatively regulate T helper type 1 immunity. Nature Immunol 2005;6:1245-52.
41. Wang F, He W, Yuan J et al. Activation of Tim-3 galectin pathway improves survival of fully allogeneic skin grafs. Transpl Immunol 2008;19:12-9.
42. Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent msenchymal stromal cells employ galectin-1 to inhibit immune effector cells. Blood, prepublished online July 19 2010; doi: .
43. Ilarregui JM, Croci DO, Bianco GA et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009;10:981-91.
44. Kim J-Y, Kim DH, Kim DS, et al. Galectin-3 secreted by human umbilical cord blood-derived mesenchymal stem cells reduces amyloid-β42 neurotoxicity in vitro. FEBS Lett 2010; doi: .
45. Baum LG, Blackall DP, Arias-Magallano S et al. Amelioration of graft versus host disease by galectin-1. Clin Immunol 2003;109:295-307.
46. Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-45.
47. Li MO, Sanjabi S, Flavel RA. Transforming growth factor-beta controls development, homeostatis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006;25:455-71.
48. Janssens W, Carlier V, Wu B, VanderElst L, Jacquemin MG, Saint Remy JM. CD4+ CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003;171:4604-12.
49. Cao X, Cai SF, Fehniger TA et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007;27:635-46.
50. Kubach J, Lutter P, Bopp T et al. Human CD4+ CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 2007;110:1550-8.
51. Garín MI, Chu CC, Golshayan D et al. Galectin-1: a key effector of regulation mediated by CD4+ CD25+ T cells. Blood 2007;109:2056-8.
52. Toscano MA, Commodaro AG, Ilarregui JM et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol 2006;176:6323-32.
53. Blois SM, Ilarregui JM, Tometten M et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nature Med 2007;13:1450-7.
54. Peng W, Wang HY, Miyahara Y, Peng G, Wang RF. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 2008;68:7228-36.
55. Rubinstein N, Alvarez M, Zwirner NW et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor immune privilege. Cancer Cell 2004;5:241-51.
56. Jones RB, Ndhlovu LC, Barbour JD et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205:2763-79.
57. Golden-Mason L, Palmer BE, Kassam N et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009;83:9122-30.